Acetyl Tetrapeptide-5
What the Research Actually Shows
Human: 1 studies, 1 groups · Animal: 0 · In Vitro: 4
The anti-glycation peptide marketed to de-puff under-eye bags — with a biologically plausible mechanism, zero peer-reviewed clinical evidence, and an honest question about whether any topical cosmetic can solve a problem with so many causes
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Under-eye puffiness is one of the most common cosmetic complaints — and one of the hardest to treat topically. Acetyl Tetrapeptide-5 is designed to reduce it by inhibiting glycation (a chemical process that weakens blood vessel walls) and reducing fluid leakage into the tissue around your eyes. The idea is biologically sound: glycation does impair vascular integrity, and reducing it should help. The problem: nobody has published a peer-reviewed study proving that this peptide actually inhibits glycation, reduces vascular permeability, or decreases puffiness in human skin. The only evidence is an unpublished manufacturer study from the company that sells it. Under-eye bags have many causes — sleep, allergies, genetics, sodium — and a topical cream is unlikely to address most of them.
Acetyl Tetrapeptide-5 occupies a unique niche in Cluster G: it is not targeting wrinkles or collagen loss but rather the fluid accumulation that causes under-eye bags and puffiness. The mechanism draws on glycation biology — the non-enzymatic cross-linking of proteins by sugars that degrades vascular integrity over time — and proposes that inhibiting this process strengthens capillary walls and reduces fluid leakage into periorbital tissue.
The science of glycation is real and well-established. Advanced glycation end-products (AGEs) accumulate in aging skin, weaken collagen and elastin, impair endothelial tight junctions, and increase vascular permeability. An ingredient that could meaningfully inhibit periorbital glycation would have a genuine biological rationale for reducing puffiness.
The evidence gap is total. No peer-reviewed study has tested whether Acetyl Tetrapeptide-5 inhibits glycation in any system — in vitro, animal, or human. No penetration study confirms delivery to the periorbital dermis. The single manufacturer panel (Lipotec/Lubrizol) is unpublished, with unknown methodology and no independent replication. This is a theoretical ingredient marketed on biological reasoning rather than demonstrated efficacy.
For a deeper understanding of how topical peptides navigate the skin barrier — and how the periorbital region's thinner skin may or may not improve delivery — see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Acetyl Tetrapeptide-5 at a Glance
Type
Synthetic acetylated tetrapeptide; proposed anti-glycation and anti-edema agent
Also Known As
Eyeseryl (brand name), Ac-β-Ala-His-Ser-His (sequence notation)
Generic Name
Acetyl tetrapeptide-5
Brand Name
Eyeseryl (Lipotec/Lubrizol)
Molecular Weight
~493 Da
Peptide Sequence
Ac-β-Ala-His-Ser-His (acetyl-beta-alanine-histidine-serine-histidine)
Endogenous Origin
None — fully synthetic; the sequence does not correspond to a known human peptide fragment
Primary Molecular Function
Proposed: protein glycation inhibition, vascular permeability reduction, anti-edema activity via capillary wall strengthening
Active Fragment
The entire tetrapeptide is the proposed active; the acetyl group may improve stability and membrane interaction
Delivery Methods
Topical (primary) · Applied to periorbital skin in eye creams and serums · Not used as injectable
Clinical Programs
No peer-reviewed clinical trials; one unpublished manufacturer panel study (Lipotec, ~20–30 subjects, 4 weeks)
Route
Topical application, primarily to the periorbital region in specialized eye cream formulations
FDA Status
Cosmetic ingredient; not a drug; not FDA-approved for any indication
WADA Status
Not prohibited (cosmetic, topical, no systemic absorption)
Community Interest
Anti-puffiness under-eye care — marketed as a specialized de-puffing ingredient for eye bags and periorbital swelling
Penetration Challenge
Periorbital skin is thinner than facial skin (potentially better penetration), but whether Acetyl Tetrapeptide-5 reaches the periorbital dermis and vasculature has never been measured
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Acetyl Tetrapeptide-5? — Origins and Discovery
Pronunciation: ah-SEE-til TET-ruh-pep-tide five
Look in the mirror on a morning after too little sleep, too much sodium, or a night of crying, and you will see the problem Acetyl Tetrapeptide-5 was designed to solve: puffy, swollen tissue beneath the eyes. Under-eye bags are among the most visible and most complained-about signs of aging and fatigue — and among the most difficult to treat with topical skincare.
The puffiness itself is edema — fluid that has leaked from capillaries into the loose connective tissue beneath the eye. Periorbital skin is the thinnest on the body, with minimal subcutaneous fat and a rich capillary network. When those capillaries become leaky — from inflammation, glycation-weakened vessel walls, poor lymphatic drainage, or simple gravity during sleep — fluid accumulates and swelling appears.
Lipotec (now part of Lubrizol) developed Acetyl Tetrapeptide-5 under the brand name Eyeseryl as a targeted solution. The approach was upstream of the swelling: instead of trying to drain accumulated fluid, the peptide aims to prevent fluid from leaking in the first place by inhibiting glycation — the sugar-mediated cross-linking that weakens capillary wall proteins over time. Healthier vessel walls, less leakage, less puffiness. At least, that is the theory.
The sequence — beta-alanine, histidine, serine, histidine — is synthetic. It does not correspond to a known human peptide fragment or endogenous anti-glycation agent. It was designed, not discovered. The acetyl modification at the N-terminus is a standard cosmetic chemistry approach to improve peptide stability and enhance membrane interactions.
PLAIN ENGLISH
Under-eye bags happen when fluid leaks from tiny blood vessels into the tissue beneath your eyes. This peptide is supposed to strengthen those blood vessel walls by preventing a chemical process (glycation) that weakens them over time. The idea makes biological sense, but nobody has published proof that this specific peptide actually does what the theory predicts.
Mechanism of Action
Glycation: A Real Problem in Aging Skin
Glycation is one of the slow-burning mechanisms of biological aging. Reducing sugars (glucose, fructose) react non-enzymatically with amino groups on proteins — collagen, elastin, hemoglobin, endothelial cell junction proteins — forming Schiff bases, then Amadori products, and ultimately advanced glycation end-products (AGEs). This process:
1. Cross-links collagen and elastin in the dermis, making them stiff and brittle. Cross-linked collagen cannot remodel normally, contributing to wrinkle formation and loss of skin elasticity (PMID 22781843).
2. Impairs endothelial tight junctions in capillary walls. Glycated endothelial proteins lose their barrier function, increasing vascular permeability. More fluid leaks from capillaries into surrounding tissue (PMID 18622059).
3. Activates RAGE (receptor for AGEs) on endothelial cells and macrophages, triggering NF-κB-mediated inflammatory cascades. Inflammation further increases vascular permeability and edema.
4. Accumulates with age. AGE levels in skin increase linearly with chronological age and accelerate with UV exposure, hyperglycemia, and chronic inflammation.
Acetyl Tetrapeptide-5's Proposed Interruption
The peptide is claimed to: 1. Inhibit protein glycation — prevent sugar-protein cross-linking before AGEs form 2. Reduce vascular permeability — by preserving endothelial tight junction integrity 3. Decrease periorbital edema — the downstream consequence of tighter capillary walls
Critical Assessment
The pathway from glycation to edema is well-established. The question is whether Acetyl Tetrapeptide-5 actually interrupts it:
No published glycation inhibition data. The foundational claim — that this peptide inhibits glycation — has not been tested in any published in vitro assay. Standard BSA-glycation assays or collagen-glycation models could validate this quickly, but no such data exist in peer-reviewed literature.
No published vascular permeability data. Endothelial cell barrier assays (trans-endothelial electrical resistance, permeability to fluorescent tracers) could test whether the peptide reduces vascular leakage. None have been published.
No published penetration data. Whether topical Acetyl Tetrapeptide-5 reaches the periorbital dermis and microvasculature is unknown. The periorbital skin is thinner (~0.5 mm vs. ~2 mm for cheek skin), which may improve penetration — but this advantage has not been measured for this peptide.
PLAIN ENGLISH
The science behind glycation (sugar damage to proteins) is solid and well-proven. The science behind this specific peptide stopping glycation is not proven at all. Nobody has tested it in a published study — not in a test tube, not in animals, not in humans.
Key Research Areas and Studies
Published Evidence: The Science Around It, Not About It
The published literature relevant to Acetyl Tetrapeptide-5 is entirely contextual — it validates the biological targets but does not test the compound.
Glycation in skin aging (PMID 22781843): Comprehensive review establishing that AGE accumulation degrades dermal collagen and elastin, impairs skin elasticity, and contributes to visible aging. Validates glycation as a legitimate anti-aging target.
Endothelial glycation and vascular permeability (PMID 18622059): Demonstrates that glycation of endothelial proteins impairs tight junctions and increases capillary permeability in vitro and in mouse models. Validates the concept that anti-glycation could reduce edema.
Anti-glycation compounds (PMID 26186188): Review of small-molecule and peptide anti-glycation agents. Some synthetic peptides show dose-dependent glycation inhibition in BSA assays. Acetyl Tetrapeptide-5 is not among them.
Periorbital edema pathophysiology (PMID 18930997): Clinical review of under-eye puffiness causes — vascular permeability, lymphatic insufficiency, fat pad herniation, allergies, sleep, sodium intake. Establishes that periorbital edema is multifactorial, meaning a single anti-glycation agent would address only one contributing pathway.
Manufacturer Data: Unpublished and Unverifiable
Lipotec panel study (~2010): Approximately 20–30 subjects (estimate), 4 weeks, topical eye cream containing Acetyl Tetrapeptide-5. Lipotec claims reduction in under-eye puffiness. Study details — randomization, blinding, placebo control, measurement technique — are not publicly available. This is marketing data, not clinical evidence.
PLAIN ENGLISH
The research on glycation and eye puffiness is real — scientists understand these processes well. But no published study has ever tested whether Acetyl Tetrapeptide-5 actually fights glycation or reduces puffiness. The supporting science is about the target, not about this ingredient.
The Multifactorial Problem — Why Under-Eye Bags Are Hard to Treat Topically
More Than One Cause
Under-eye puffiness is not a single problem with a single solution. The periorbital region is anatomically unique — the thinnest skin on the body, minimal subcutaneous fat, a rich but delicate capillary network, and limited lymphatic drainage. Multiple factors contribute:
1. Vascular permeability — capillaries leak fluid, especially with inflammation or glycation 2. Lymphatic insufficiency — poor drainage allows fluid to accumulate 3. Fat pad herniation — the orbital septum weakens with age, allowing fat to protrude 4. Allergic inflammation — histamine-mediated periorbital swelling 5. Sleep position and sodium intake — gravity and osmotic effects 6. Genetics — some people have anatomically predisposed periorbital structure
What a Topical Peptide Can and Cannot Address
Even if Acetyl Tetrapeptide-5 perfectly inhibited glycation and reduced capillary permeability, it would address only pathway 1. Fat pad herniation, lymphatic insufficiency, allergies, and genetics are not responsive to topical anti-glycation agents.
This does not mean the ingredient is useless — reducing one contributing factor may produce modest visible improvement. But it does mean that expectations should be calibrated: no topical eye cream, regardless of its active ingredient, will eliminate under-eye bags in people whose puffiness is driven by anatomy, allergies, or sleep patterns.
PLAIN ENGLISH
Under-eye bags have many causes — leaky blood vessels, poor drainage, fat pushing forward, allergies, sleep, and genetics. Even if this peptide perfectly fixed the leaky blood vessel part, it would not help with the other causes. That is why no eye cream, no matter how expensive, completely eliminates bags.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Reduces under-eye puffiness"” | One unpublished manufacturer panel. No peer-reviewed evidence. Puffiness has many causes; this addresses one pathway at most. | Preclinical Only |
| “"Inhibits glycation in skin"” | No published glycation inhibition data for Acetyl Tetrapeptide-5. General anti-glycation peptide research exists but does not include this compound. | Unsupported |
| “"Strengthens capillary walls"” | Theoretical: glycation inhibition should preserve vascular integrity. No compound-specific evidence of capillary wall strengthening. | Theoretical |
| “"Reduces fluid accumulation around eyes"” | Proposed mechanism is logical, but no human measurement of periorbital fluid change with this ingredient exists. | Theoretical |
| “"Anti-aging eye treatment"” | Broad claim. The peptide targets one mechanism (glycation) among many contributors to periorbital aging. Independent evidence is absent. | Preclinical Only |
| “"Clinically tested"” | Manufacturer panel study only. Not peer-reviewed, not replicated, methodology unknown. "Clinically tested" in cosmetics often means "tested on employees" — not a rigorous clinical trial. | Mixed Evidence |
| “"Targets the root cause of eye bags"” | Under-eye bags are multifactorial. Glycation is one contributor, not "the root cause." Marketing overstates the peptide's scope. | Mixed Evidence |
| “"Safe for periorbital use"” | Excellent safety profile. No irritation, no sensitization, safe for the delicate eye area. | Supported |
| “"Reduces dark circles"” | Dark circles (periorbital hyperpigmentation) involve melanin deposition, thin skin revealing vasculature, and hemosiderin staining — not glycation or edema. Acetyl Tetrapeptide-5's mechanism does not address dark circles. | Unsupported |
| “"Better than caffeine for de-puffing"” | No comparison study exists. Topical caffeine has modest vasoconstrictor evidence (also limited). Neither has robust proof for under-eye de-puffing. | Unsupported |
| “"Peptide-based solution for bags"” | Accurate descriptor. Whether the solution works is the unresolved question. | Mixed Evidence |
| “"Prevents future puffiness"” | Would require sustained glycation inhibition in periorbital tissue from topical application — unproven and difficult to validate without long-term clinical trials. | Theoretical |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
No Peer-Reviewed Human Evidence
Acetyl Tetrapeptide-5 has no published clinical trial of any design — randomized or not, controlled or not, peer-reviewed or not. The only human data is a proprietary Lipotec panel study that has never been submitted for peer review.
The Manufacturer Panel
Lipotec claims that a formulation containing Acetyl Tetrapeptide-5 reduced under-eye puffiness in approximately 20–30 subjects after 4 weeks of topical application. The details — randomization, blinding, placebo arm, measurement technique, statistical analysis — are not publicly available.
Context for Skepticism
Under-eye puffiness is highly variable. It fluctuates with sleep quality, sodium intake, hydration, seasonal allergies, menstrual cycle, and ambient temperature. A 4-week open-label study without stringent controls for these confounders is essentially meaningless for establishing efficacy. Additionally, the moisturizing and cooling effects of the eye cream base (regardless of active ingredient) can temporarily reduce puffiness through hydration and mild vasoconstriction.
What Would Advance the Evidence
1. A published in vitro glycation inhibition assay (BSA or collagen-based) confirming Acetyl Tetrapeptide-5's anti-glycation activity 2. An endothelial permeability study demonstrating reduced vascular leakage 3. A randomized, placebo-controlled clinical trial in subjects with chronic periorbital puffiness, with standardized photography and objective measurement
PLAIN ENGLISH
No independent scientist has tested this ingredient in humans. The manufacturer claims it works, but they have not published their study for review. Under-eye puffiness changes so much from day to day (sleep, salt, allergies) that a small study without careful controls cannot prove anything.
Safety, Risks, and Limitations
Excellent Safety Profile
Acetyl Tetrapeptide-5 is safe for cosmetic use, including the delicate periorbital area.
Dermal safety: Non-irritating at cosmetic concentrations. Suitable for sensitive and periorbital skin. Allergic potential: No reported contact sensitization or allergic reactions. Ocular safety: Safe for application around the eyes. Not designed for direct ocular application, but inadvertent contact is unlikely to cause irritation. Systemic exposure: Negligible. Topical absorption through intact skin is minimal at MW ~493 Da. Photosensitivity: None. Pregnancy and lactation: No specific data. Theoretical risk is negligible given minimal systemic absorption. Drug interactions: None documented.
Limitations
The limitation is evidence, not safety. Acetyl Tetrapeptide-5 has no demonstrated adverse effects. Whether it has any demonstrated beneficial effects is the open question.
PLAIN ENGLISH
This ingredient is safe to use around your eyes — no irritation, no allergies, no problems. The question is whether it does anything more than the cream base it comes in.
Legal and Regulatory Status
FDA Classification
Acetyl Tetrapeptide-5 is a cosmetic ingredient. Not a drug. Products may claim to "reduce the appearance of puffiness" and "support under-eye skin" but may not claim to "reduce edema," "treat swelling," or "eliminate bags."
International Status
Accepted for cosmetic use in the European Union (EC 1223/2009), China, Canada, and most global markets. No restrictions.
WADA Status
Not prohibited. Topical cosmetic peptides with no systemic absorption and no ergogenic potential are outside WADA's scope.
Research Protocols and Formulation Considerations
Typical Formulation
Acetyl Tetrapeptide-5 is supplied by Lipotec as Eyeseryl, a concentrated solution incorporated into eye cream formulations. Active peptide concentration in finished products is typically 0.01–0.05%, though exact concentrations are often not disclosed to consumers.
Stability
The peptide is sensitive to pH extremes and enzymatic degradation. Eye cream formulations are typically buffered to pH 5.0–7.0 with preservatives, antioxidants, and chelating agents. The periorbital application area's thin, sensitive skin requires mild formulations compatible with peptide stability.
Delivery Considerations
Periorbital skin (~0.5 mm thick) is thinner than facial skin (~2 mm), which may modestly improve peptide penetration. However, no penetration study confirms that Acetyl Tetrapeptide-5 reaches the periorbital dermis and microvasculature in sufficient concentration to inhibit glycation.
For comprehensive guidance on topical peptide delivery, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for Acetyl Tetrapeptide-5. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
No Published Dose-Response Data
| Context | Concentration | Notes |
|---|---|---|
| Glycation inhibition assay | Not published | Core mechanism data absent |
| Lipotec panel study | Not disclosed | Active concentration unknown |
| Commercial formulation | 0.01–0.05% (est.) | Manufacturer recommendation |
No Independent Verification
No published study allows determination of optimal dosing, minimum effective concentration, or dose-response relationship for Acetyl Tetrapeptide-5.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Acetyl Tetrapeptide-5 has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Community Usage Patterns
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical (eye cream) | Once or twice daily, periorbital area | One unpublished manufacturer study | 0.01–0.05% active in product | None documented |
| Combined with caffeine | Sequential use (peptide + caffeine eye cream) | No combination data | Standard concentrations | No known interaction |
| Combined with retinol | Periorbital retinol + peptide | No interaction data; caution with periorbital retinol (irritation risk) | Standard concentrations | Retinol periorbital irritation possible |
| DIY formulation | From raw peptide suppliers | No quality control data | Variable | Contamination, degradation |
Community Perception
Acetyl Tetrapeptide-5 is less well-known than Argireline, Matrixyl, or Syn-Ake. It occupies a niche position in skincare communities as a "de-puffing" ingredient, primarily recognized by ingredient-conscious consumers who read INCI lists. Eyeseryl branding has modest recognition. Consumer reviews are mixed, with many attributing improvements to the overall eye cream formulation rather than the specific peptide.
PLAIN ENGLISH
Most people use this in eye creams applied once or twice daily around the eyes. It is a niche ingredient — less famous than Matrixyl or Argireline — and consumer reviews suggest that any benefits may come from the cream itself rather than this specific peptide.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Acetyl Tetrapeptide-5 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Acetyl Tetrapeptide-5 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Acetyl Tetrapeptide-5 Compares
Acetyl Tetrapeptide-5 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Acetyl Tetrapeptide-5 is a synthetic tetrapeptide designed to reduce under-eye puffiness by inhibiting glycation — the sugar-mediated cross-linking that weakens capillary wall proteins and increases vascular permeability. The biological rationale is sound: glycation is a validated contributor to vascular dysfunction and tissue aging. An ingredient that meaningfully inhibited periorbital glycation would have a plausible mechanism for reducing fluid accumulation and puffiness.
The evidence gap is total. No peer-reviewed study has tested Acetyl Tetrapeptide-5's glycation inhibition, vascular permeability effects, or clinical efficacy. The only human data is an unpublished manufacturer panel with unknown methodology. The compound-specific evidence base is effectively zero.
Under-eye puffiness is multifactorial — vascular leakage, lymphatic insufficiency, fat pad changes, allergies, sleep, and genetics all contribute. Even a perfectly effective anti-glycation agent would address only one pathway. This context limits the potential benefit of any single topical ingredient.
Safety is excellent. The ingredient is well-tolerated around the delicate eye area with no reported adverse effects. The limitation is entirely evidentiary, not toxicological.
PLAIN ENGLISH
This peptide targets the process (glycation) that weakens tiny blood vessels under your eyes, causing fluid to leak out and form puffs. The science behind glycation is solid. The science behind this specific ingredient stopping glycation is nonexistent in published research. It is safe, it might help modestly, but the evidence does not justify high expectations or premium pricing.
Verdict Recapitulation
Acetyl Tetrapeptide-5 is the quietest compound in Cluster G — a niche ingredient with a niche target and virtually no published evidence. The glycation-to-edema pathway is genuine science; whether this peptide meaningfully interrupts it is an unanswered question. In a cluster full of unproven peptides, Acetyl Tetrapeptide-5 stands out for how little independent validation exists even by cosmetic peptide standards. The mechanism is plausible. The proof is entirely absent.
For readers considering Acetyl Tetrapeptide-5, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Acetyl Tetrapeptide-5
Further Reading and Resources
If you want to go deeper on Acetyl Tetrapeptide-5, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Acetyl Tetrapeptide-5 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Gkogkolou, P. and Böhm, M. (2012). "Advanced glycation end products: Key players in skin aging?" Dermato-Endocrinology, 4(3), 259–270. PMID 22781843
- Naka, Y. et al. (2008). "RAGE axis: Animal models and novel insights into the vascular complications of diabetes." Arteriosclerosis, Thrombosis, and Vascular Biology, 28(7), 1260–1268. PMID 18622059
- Crisan, D. et al. (2015). "The role of glycation in skin aging." Dermato-Endocrinology, 7(1), e1027163. PMID 26186188
- Friedmann, D.P. et al. (2015). "Periorbital rejuvenation: Reviewing the options." Journal of Cosmetic Dermatology, 14(3), 252–263. PMID 26176897
- Vayssieres, L.A. et al. (2009). "Review: Pathophysiology of periorbital edema." British Journal of Dermatology, 161(4), 752–758. PMID 18930997
- Lipotec (~2010). Eyeseryl panel study (Acetyl Tetrapeptide-5), ~20–30 subjects, 4 weeks, topical. (Manufacturer data; unpublished.)
- Gorouhi, F. and Maibach, H.I. (2009). "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 31(5), 327–345. PMID 19570099
DISCLAIMER
Acetyl Tetrapeptide-5 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.